Example: tourism industry
Information to be included with an application for ...
Morphine by mouth Morphine can be given as: a simple aqueous solution of the sulfate or hydrochloride salt every four hours (an antimicrobial preservative may be added); tablets, every 4
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
Position Paediatric Age Categories to be Used in ...
archives.who.intPosition Paper Paediatric Age Categories to be Used in Differentiating Between Listing on a Model Essential Medicines List for Children
APPLICATION FOR INCLUSION OF RIBAVIRIN IN …
archives.who.int07 Nov. 06 ribavirin.doc 1/31 The Secretary of the Expert Committee on the Selection and Use of Essential Medicines Policy, Access and Rational Use
EXTERNAL REVIEW – THEOPHYLLINE - WHO archives
archives.who.intThis review therefore considers the evidence for the possible deletion of theophylline as a specific oral methylxanthine in relation to the listed
SODIUM VALPROATE IN CHILDHOOD EPILEPSY - …
archives.who.intSodium valproate page 1 SODIUM VALPROATE IN CHILDHOOD EPILEPSY Report prepared for the World Health Organisation November 2006 1. Summary statement of the proposal for inclusion, change or
Cardiovascular drugs - WHO archives
archives.who.intAntianginal drugs The three main types of angina are: • stable angina (angina of effort), where atherosclerosis restricts blood flow in the coronary vessels; attacks are usually caused by exertion and relieved by rest • unstable angina (acute coronary insufficiency), which is considered to be an intermediate stage between stable angina and myocardial infarction
Gastrointestinal drugs - WHO archives
archives.who.intthose related to NSAID use). Eradication of H. pylori reduces the relapse rate to about 4–8%. This is undoubtedly cost-effective compared to the alternatives of long-term maintenance therapy with low-dose H 2-receptor antagonists or repeated treatment of recurrent ulcers.
Related documents
Tapentadol (Palexia®) prolonged and immediate release ...
gmmmg.nhs.ukNovember 2015 Tapentadol (Palexia®) prolonged and immediate release tablets for the treatment of acute and chronic severe pain. The New Therapies Subgroup of the Greater Manchester Medicines
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF …
db.cbg-meb.nlSUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Valproate chrono 300 mg prolonged-release tablets Valproate chrono 500 mg prolonged-release tablets
GLUCOPHAGE SR 1000MG PROLONGED-RELEASE TABLETS …
www.mhra.gov.ukPAR Glucophage SR 1000 mg prolonged release tablets PL 11648/0067 7 II.3 Medicinal Product Pharmaceutical Development The objective of the development programme was to formulate a globally acceptable and stable product
AUSTRALIAN PRODUCT INFORMATION BETMIGA …
www.medicines.org.au1 AUSTRALIAN PRODUCT INFORMATION BETMIGA® (MIRABEGRON) PROLONGED-RELEASE FILM-COATED TABLETS 1 NAME OF THE MEDICINE Mirabegron 2 QUALITATIVE AND QUANTITATIVE COMPOSITION BETMIGA contains mirabegron 25 …
AUSTRALIAN PRODUCT INFORMATION SIFROL® …
www.medicines.org.auSIFROL and SIFROL ER PI0130-11 Page 3 In case a dose is missed, SIFROL ER prolonged-release tablets should be taken up to 12 hours after the regular time.
Focalin™ XR - Food and Drug Administration
www.accessdata.fda.govdifference was not statistically significant, and these patterns remained even after weight normalization. Pharmacokinetic parameters for dexmethylphenidate after Focalin immediate release tablets were …
Public Assessment Report Decentralised Procedure - GOV.UK
www.mhra.gov.ukPAR Mariosea, Dengaff and Trillblad XL 2 mg and 4 mg Prolonged-release Capsules UK/H/4976/001-2/DC UK/H/4977-8/001/DC 2 LAY SUMMARY Mariosea XL 2 mg Prolonged-release Capsules
HIGHLIGHTS OF PRESCRIBING INFORMATION orally twice …
www.nucynta.com1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NUCYNTA® ER safely and effectively. See full prescribing information for NUCYNTA® ER NUCYNTA® ER (tapentadol) extended-release tablets for oral use C-II Initial U.S. Approval: 2008
Reference ID: 4036863 - Food and Drug Administration
www.accessdata.fda.govhave been reported with methylphenidate products. Immediate medical attention should be sought if sign penile erections or priapism are observed
Related search queries
Prolonged and immediate release, Prolonged and immediate release tablets, SUMMARY OF PRODUCT CHARACTERISTICS 1, Prolonged, Release tablets, Prolonged release tablets, PROLONGED-RELEASE FILM-COATED TABLETS, SIFROL, Focalin™ XR, Food and Drug Administration, Immediate release tablets, Prolonged-release Capsules, Mariosea XL, Immediate